Charles River Laboratories International, Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. The fiscal year included a 53rd week. This is an annual filing; standalone fourth-quarter financial results are not clearly provided in the filing text.
Business context
Charles River is a global non-clinical drug development and research partner, operating through Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. DSA generated 61.6% of revenue; RMS 18.6%; Manufacturing 19.8%.
Financial results and liquidity
| Metric | FY2022 | FY2021 | Change |
|---|---|---|---|
| Revenue | $3.976 billion | $3.540 billion | +12.3% |
| Operating income | $651.0 million | $589.9 million | +10.4% |
| Operating margin | 16.4% | 16.7% | -30 bps |
| Net income attributable to common shareholders | $486.2 million | $391.0 million | +$95.2 million |
| Diluted EPS | $9.48 | $7.60 | +24.7% |
| Operating cash flow | $619.6 million | $760.8 million | -$141.2 million |
| Capital expenditures | $324.7 million | $228.8 million | +$96.0 million |
Operating cash flow less capital expenditures was approximately $294.9 million, calculated from reported figures. Cash and short-term investments totaled $234.9 million at year-end, versus $242.3 million a year earlier. Total debt and finance leases were approximately $2.73 billion; reported debt was $2.70 billion. The $3.0 billion revolving facility had $1.20 billion outstanding, implying about $1.80 billion of nominal unused capacity. The company reported compliance with its financial covenants.
Segment revenue and operating margin: RMS $739.2 million and 21.7% (prior year 24.2%); DSA $2.447 billion and 21.8% (prior year 19.3%); Manufacturing $789.6 million and 21.2% (prior year 33.2%).
Material changes versus FY2021
- Revenue growth reflected higher demand and pricing, particularly in DSA, acquisitions, and the 53rd week; foreign exchange reduced reported growth. Service revenue rose 16.7%, while product revenue fell 3.2%.
- DSA operating income rose 30.9%, supported by stronger demand and pricing. RMS operating income fell 3.8%, and Manufacturing operating income fell 32.2%, reflecting costs and acquisition-related amortization in the latter.
- Net income benefited from a $123.4 million gain on the December 2022 Avian Vaccine Services divestiture. The higher effective tax rate—20.9% versus 17.0%—partly offset the improvement.
- Operating cash flow declined amid working-capital timing, increased inventory purchases, and higher variable compensation. Capital expenditures increased to support growth.
Outlook, commentary, risks, and unusual items
- Management described demand and pricing as strong across segments in 2022, with small and mid-sized biotechnology clients a key growth driver. Discovery Services demand increased but moderated as some customers took longer to start projects.
- No specific numerical revenue or earnings guidance for a future period is provided in the filing text. Management stated that available funds, operating cash generation, and financing access were expected to fund operations for the foreseeable future.
- CDMO performance was pressured by the loss of a large COVID-19 project and integration-related costs and investments. Management said initiatives to improve performance were beginning to gain traction.
- Non-human primate supply and investigation: In February 2023, after year-end, the company disclosed DOJ and USFWS investigations concerning several Cambodia-origin shipments and a grand jury subpoena. It suspended future Cambodia shipments pending agreed procedures. The company said the outcome, timing, and potential penalties or liabilities could not be predicted; approximately $20 million of inventory related to certain shipments remained in its care.
- Other notable exposures include limited-source non-human primate supply, client study cancellations or delays, competition and possible non-animal testing alternatives, regulatory and data-integrity requirements, foreign exchange, inflation, cybersecurity, and acquisition integration.
- The Avian divestiture generated $169 million preliminary cash consideration, plus possible contingent payments up to $30 million. The company also acquired Explora BioLabs for $284.5 million in 2022.
Important facts for investors to verify
- Review subsequent disclosures on the DOJ/USFWS investigation, Cambodia supply restrictions, and the status and recoverability of the related inventory.
- Assess whether DSA demand and backlog convert to revenue and cash, and whether the lower DSA project-start pace persists.
- Track Manufacturing/CDMO margins and integration costs, and determine whether management’s improvement initiatives deliver sustained results.
- Evaluate debt, floating-rate exposure, refinancing and covenant headroom; the company had $2.7 billion of debt and finance leases at year-end.
- Separate recurring earnings from the $123.4 million Avian divestiture gain and account for the 53rd week when comparing periods.
- Note that the auditor issued an unqualified opinion and found internal control over financial reporting effective; Explora BioLabs was excluded from the year-end control assessment.